Hereditary amyloidosis (hATTR)

The FDA today granted Alnylam Pharmaceuticals approval for a first-in-class small interfering ribonucleic acid (siRNA) treatment-the first therapy indicated for…

The US Food and Drug Administration (FDA) has approved inotersen (Tegsedi, Akcea Therapeutics and Ionis Pharmaceuticals) for the treatment of polyneuropathy (PN) in…

A new hereditary ATTR (hATTR) amyloidosis treatment, inotersen, an investigational antisense drug, may not be far from a US Food and Drug Administration (FDA)…

As a caregiver for a loved one with hATTR amyloidosis, you begin to take on new role in your relationship. This often requires a major lifestyle change with new…

After being diagnosed with hATTR amyloidosis, it is normal to have a wide range of feelings and have questions about how your diagnosis will change your daily…